Search

Syndax Pharmaceuticals Inc

Open

SectorGezondheidszorg

17.52 -3.79

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.48

Max

18.25

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.7M

-49M

Verkoop

7.9M

73M

EPS

-0.55

Winstmarge

-67.817

Werknemers

298

EBITDA

-5.9M

-37M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+104.9% upside

Dividenden

By Acuity

Volgende Winsten

2 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-110M

1.6B

Vorige openingsprijs

21.31

Vorige sluitingsprijs

17.52

Nieuwssentiment

By Acuity

50%

50%

94 / 339 Rangschikking in Healthcare

Syndax Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 okt 2026, 20:07 UTC

Social Media

Shares of Syndax Pharmaceuticals fell despite positive analyst ratings from H.C. Wainwright and Jefferies, remaining below the 20-day moving average.

30 sep 2026, 20:07 UTC

Syndax Pharmaceuticals Inc is experiencing gains in Wednesday's trading session, rebounding significantly after an early dip and achieving a notable cumulative return since Tuesday.

29 sep 2026, 23:30 UTC

Syndax Pharmaceuticals Inc is rising in after-market trading, advancing from a low point post-market close and currently near the midpoint of its one-month trading range.

28 sep 2026, 19:16 UTC

News

Syndax Pharmaceuticals Inc. shares fell, remaining below the 20-day moving average despite being rated a "Strong Buy" following FDA approval for Revuforj.

25 sep 2026, 19:46 UTC

News
Social Media

Syndax Pharmaceuticals reaffirms over $2 billion in U.S. peak sales for Revuforj after SAVE trial results show an 88% overall response rate, driving shares higher.

24 sep 2026, 20:12 UTC

Syndax Pharmaceuticals Inc is trading higher in after-market hours, maintaining a steady position since Thursday's close, despite being below its 20-day moving average.

23 sep 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, reaching their lowest point around midday and remaining below the 20-day moving average after a significant decline from Tuesday's close.

22 sep 2026, 19:45 UTC

Syndax Pharmaceuticals Inc is trading modestly higher, though the price remains below its 20-day moving average and near the lower end of its one-month range.

21 sep 2026, 21:11 UTC

Syndax Pharmaceuticals Inc is advancing in after-market trading, reflecting notable upward movement since Monday's close, despite remaining below its 20-day moving average.

17 sep 2026, 20:07 UTC

Syndax Pharmaceuticals Inc is trading higher, having seen a steady increase, despite being below its 20-day moving average and near the lower end of its one-month range.

16 sep 2026, 20:06 UTC

Macro Event

Syndax Pharmaceuticals Inc shares fell sharply, driven by heightened volatility in the healthcare sector following the Federal Reserve's recent 25 basis point interest rate hike.

15 sep 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares are lower amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index for September.

11 sep 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, continuing a downward trend amid heightened market volatility following the August Consumer Price Index release.

10 sep 2026, 20:03 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

8 sep 2026, 20:07 UTC

News

Syndax Pharmaceuticals is lower today amid broader market weakness and speculation about a Federal Reserve interest rate hike following strong labor data.

2 sep 2026, 20:08 UTC

Syndax Pharmaceuticals Inc shares are higher today, despite earlier pulling back from a session high amid broader market volatility and slower job growth indicators.

1 sep 2026, 20:09 UTC

News

Syndax Pharmaceuticals shares are higher as the company announces participation in two investor conferences to boost visibility for its cancer therapies.

25 aug 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

24 aug 2026, 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

21 aug 2026, 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

20 aug 2026, 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

19 aug 2026, 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

18 aug 2026, 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

17 aug 2026, 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

14 aug 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

12 aug 2026, 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

11 aug 2026, 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

10 aug 2026, 19:36 UTC

Syndax Pharmaceuticals shares are lower amid broader market volatility and rising oil prices due to geopolitical tensions in the Strait of Hormuz.

6 aug 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, facing volatility amid broader market conditions and recent economic data impacting Federal Reserve policy.

5 aug 2026, 20:02 UTC

News
Social Media

Syndax Pharmaceuticals shares rise after H.C. Wainwright maintains Buy rating and lowers price target to $38, citing strong revenue growth of $73 million.

Peer Vergelijking

Prijswijziging

Syndax Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

104.9% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 37.333 USD  104.9%

Hoogste 57 USD

Laagste 26 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Syndax Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Sentiment

By Acuity

94 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.